Patricia Inácio, PhD,  science writer—

Acquired angioedema was the first sign of an underlying extranodal marginal zone lymphoma (EMZL) — a type of non-Hodgkin lymphoma — in a 45-year-old woman, according to a case study. After a comprehensive evaluation involving cancer and immunology specialists, she received treatment with rituximab. The therapy resolved her…

New hereditary angioedema (HAE) preventive treatment Dawnzera (donidalorsen) will now be available in the U.S. to adults and adolescents, ages 12 and older, through the specialty pharmacy Orsini. Following the therapy’s approval late last month as a prophylaxis for HAE swelling attacks, developer Ionis Pharmaceuticals partnered with…

Hereditary angioedema (HAE) patients who took Takhzyro (lanadelumab-flyo) for at least three years saw reductions in the frequency and severity of attacks and found that their quality of life improved, data from a U.S. study showed. The study, “Long-term Real-world Outcomes in Patients with Hereditary Angioedema…

The oral on-demand treatment candidate sebetralstat for hereditary angioedema (HAE) is getting to keep its orphan drug status in the European Union, developer Kalvista Pharmaceuticals announced. According to a press release from the company, the European Medicines Agency (EMA) has decided to maintain the therapy’s orphan drug designation,…

Delays in administering on-demand treatment are common in hereditary angioedema (HAE), with 51% of patients receiving treatment more than two hours after the onset of an attack, according to a survey in Italy that found that delaying treatment correlates with greater attack severity. The findings underscore the need to…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that sebetralstat be approved as an on-demand treatment for acute attacks in people with hereditary angioedema (HAE), ages 12 and older. “This positive CHMP opinion is an important step forward for people living…

A woman was diagnosed with hereditary angioedema (HAE) 20 years after her first symptoms, according to a case report in Nepal. The case highlights “the importance of early diagnosis and effective management to alleviate patient suffering,” the report’s researchers wrote. The case report, “A Two-Decade-Delayed Diagnosis…

The first patient has been dosed in a Phase 3 clinical trial testing NTLA-2002, Intellia Therapeutics’ gene-editing treatment candidate for hereditary angioedema (HAE). The trial, called HAELO (NCT06634420), is expected to enroll an estimated 60 adults with HAE types 1 or 2; it’s recruiting participants at five…

Astria Therapeutics is on track to start a Phase 3 clinical trial of navenibart, its therapy to prevent swelling attacks in people with hereditary angioedema (HAE), by March. The trial, dubbed ALPHA-ORBIT, will test flexible dosing schedules, with navenibart being given every three months and every six months.

Treatment with navenibart, or STAR-0215, safely reduced the rate of monthly swelling attacks by 90% to 95% in people with hereditary angioedema (HAE) when the therapy was given once or twice over six months, data from the completed Phase 1/2 ALPHA-STAR clinical trial shows.